摘要
Abstract
Objective To investigate the effects of Tiotropium bromide combined with Salmeterol/Fluticasone on the pulmonary function and dyspnea indexes in patients with moderate-severe chronic obstructive pulmonary disease (COPD). Method From October 2015 to November 2016, 102 patients with moderate-severe COPD treated in our hospital were selected as the study subjects, and they were divided into group A, group B and group C according to the random number method, 34 cases in each group. Group A patients were treated by Tiotropium bromide combined with Salmeterol/Fluticasone, while group B patients were treated by Tiotropium bromide and group C patients were treated by Salmeterol/Fluticasone. Compared the pulmonary function [forced expiratory volume in the first second (FEV1), forced vital capacity (FEV1% pred), FEV1% of FVC (FEV1/FVC), functional residual capacity (FRC), inspiratory capacity (IC)], blood gas values [arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2)], modified medical research council (mMRC), COPD assessment test (CAT) score, 6-minutes walk test (6WMT),treatment efficiency rate and adverse drug reaction rate among the three groups. Result The pulmonary function (FEV1, FVC, FEV1%pred, FEV1/FVC, FRC, IC), PaO2, PaCO2, mMRC score, CAT score and 6WMT of group A significantly improved more than the other two groups (P<0.05), while group C improved more than group B (P<0.05). The treatment effective rate of group A was significantly higher than that of group B and group C (P < 0.05), while there was no significant difference between group B and group C (P >0.05). There were no significant differences of adverse drug reaction rates between group A and group C (P>0.05), which were both higher than that of group B (P<0.05). Conclusion Tiotropium bromide combined with Salmeterol/Fluticasone can significantly improve lung functions of moderate-severe COPD patients, and effectively relieve dyspnea symptoms, improve prognosis and quality of life. And Salmeterol/Fluticasone has better effects on lung functions and dyspnea relive than Tiotropium. However, group A and group C have more adverse drug reactions and lower safety than group B, because of glucocorticoid. Therefore, short-course treatment is recommended clinically.关键词
噻托溴铵/慢性阻塞性肺疾病/肺功能/沙美特罗替卡松Key words
Tiotropium bromide/Salmeterol/fluticasone/COPD/Lung function
